Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.210
-0.010 (-0.82%)
At close: Jun 17, 2025, 4:00 PM
1.210
0.00 (0.00%)
After-hours: Jun 17, 2025, 5:55 PM EDT
Acrivon Therapeutics Stock Forecast
ACRV's stock price has decreased by -83.31% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 7 analysts that cover Acrivon Therapeutics stock have a consensus rating of "Buy" and an average price target of $17.6, which forecasts a 1354.55% increase in the stock price over the next year. The lowest target is $9 and the highest is $27.
Price Target: $17.6 (+1354.55%)
Analyst Consensus: Buy
* Price targets were last updated on May 15, 2025.
Analyst Ratings
The average analyst rating for Acrivon Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Buy | 4 | 4 | 4 | 4 | 4 | 4 |
Hold | 0 | 0 | 0 | 0 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 6 | 6 | 6 | 6 | 7 | 7 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Jones Trading | Jones Trading | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 16, 2025 |
Oppenheimer | Oppenheimer | Buy Maintains $10 → $9 | Buy | Maintains | $10 → $9 | +643.80% | May 15, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +1,470.25% | Mar 28, 2025 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Mar 26, 2025 |
Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $17 | Buy | Reiterates | $17 | +1,304.96% | Mar 26, 2025 |
Financial Forecast
Revenue This Year
n/a
from 109.92M
Revenue Next Year
n/a
EPS This Year
-2.45
from -2.38
EPS Next Year
-2.56
from -2.45
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 1.2M | 11.0M | 45.1M | ||
Avg | 147,900 | 1.9M | 12.8M | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -98.9% | 7,354.4% | 2,246.2% | ||
Avg | -99.9% | 1,200.2% | 564.5% | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -2.21 | -2.14 | -1.88 | ||
Avg | -2.45 | -2.56 | -2.55 | ||
Low | -2.84 | -3.43 | -3.97 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.